The Index
Every company in our coverage — the builders, studios and houses we write about. Each one gathers its articles, jobs and listings in a single place.
7 companies · AI-Bio
AI-Bio
A de-risked, cash-rich option on one binary — ABCL635 Phase 2 hot-flash data in Q3 2026 — wrapped around a platform whose old royalty engine has gone to zero; the antibody-vs-pill differentiation is plausible but unproven, and at ~$1.5B the market is already paying for a win.
AI-Bio
A debt-free clinical biotech trading below net cash after the FDA rejected its lead's trial design — the platform and a 4-year runway are free, but only if the EphA2/radioconjugate pivot proves the machine can make a second winner.